RO 5267683

Drug Profile

RO 5267683

Alternative Names: RO5267683

Latest Information Update: 25 Feb 2014

Price : $50

At a glance

  • Originator Roche
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Unspecified

Most Recent Events

  • 25 Feb 2014 Discontinued - Phase-I for Undefined indication in France (PO)
  • 30 Jun 2012 Roche completes a phase I trial in Healthy volunteers in France (NCT01398241)
  • 31 Aug 2011 Phase-I clinical trials in Undefined indication in France (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top